Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Johnson & Johnson, junto con sus filiales, se dedica a la investigación y el desarrollo, la fabricación y la venta de una gama de productos en el campo de la atención sanitaria en todo el mundo. Opera en dos segmentos, Medicina Innovadora y MedTech. El segmento de Medicina Innovadora ofrece productos para diversas áreas terapéuticas, como oncología, inmunología, neurociencia, hipertensión pulmonar, enfermedades infecciosas y cardiovasculares y metabolismo distribuidos a través de minoristas, mayoristas, distribuidores, hospitales y profesionales de la salud para uso con receta.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $97.9B | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B | $82.6B | $82.1B | $81.6B | $76.5B | $71.9B | $70.1B | $74.3B | $71.3B | $67.2B | $65.0B | $61.6B | $61.9B | $63.7B | $61.1B | $53.3B |
| Beneficio bruto | $69.0B | $68.6B | $61.4B | $58.4B | $55.4B | $55.3B | $54.2B | $54.5B | $54.5B | $51.0B | $50.1B | $48.5B | $51.6B | $49.0B | $45.6B | $44.7B | $42.8B | $43.5B | $45.2B | $43.3B | $38.3B |
| % de margen bruto | 70.5% | 72.8% | 69.1% | 68.6% | 69.2% | 70.3% | 65.6% | 66.4% | 66.8% | 66.7% | 69.7% | 69.3% | 69.4% | 68.7% | 67.8% | 68.7% | 69.5% | 70.2% | 71.0% | 71.0% | 71.8% |
| Ingresos operativos (EBIT) | $26.3B | $25.6B | $22.1B | $21.9B | $21.0B | $20.9B | $19.7B | $21.0B | $21.2B | $18.9B | $20.9B | $18.3B | $21.1B | $19.0B | $17.0B | $16.2B | $16.5B | $16.7B | $16.2B | $15.2B | $13.7B |
| % de margen operativo | 26.8% | 27.2% | 24.9% | 25.7% | 26.3% | 26.6% | 23.9% | 25.6% | 26.0% | 24.7% | 29.1% | 26.1% | 28.4% | 26.6% | 25.3% | 24.8% | 26.8% | 26.9% | 25.4% | 24.9% | 25.7% |
| Ingresos netos | $21.0B | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B | $14.7B | $15.1B | $15.3B | $1.3B | $16.5B | $15.4B | $16.3B | $13.8B | $10.9B | $9.7B | $13.3B | $12.3B | $12.9B | $10.6B | $11.1B |
| % de margen neto | 21.5% | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% | 22.0% | 22.0% | 19.4% | 16.1% | 14.9% | 21.6% | 19.8% | 20.3% | 17.3% | 20.7% |
| EBITDA | $31.9B | $41.1B | $24.8B | $29.3B | $26.6B | $26.8B | $23.9B | $24.7B | $25.9B | $24.2B | $24.3B | $23.5B | $25.0B | $20.1B | $18.0B | $16.1B | $20.3B | $19.0B | $20.2B | $16.4B | $15.9B |
| Beneficio por acción (EPS) | $8.63 | $11.03 | $5.79 | $13.73 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 | $3.73 |
| Acciones en circulación (M) | 2,440M | 2,429M | 2,429M | 2,560M | 2,664M | 2,674M | 2,671M | 2,684M | 2,729M | 2,745M | 2,789M | 2,813M | 2,864M | 2,877M | 2,813M | 2,775M | 2,789M | 2,789M | 2,836M | 2,911M | 2,963M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de JNJ. /companies/us/JNJ
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms